RAD 202
Alternative Names: RAD-202Latest Information Update: 25 Apr 2023
At a glance
- Originator Radiopharm Theranostics
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
- Preclinical Gastric cancer
Most Recent Events
- 24 Apr 2023 Preclinical trials in Gastric cancer in USA (unspecified route) (Radiopharm Theranostics pipeline, April 2023)
- 24 Jun 2022 Preclinical trials in Breast cancer in USA (IV), prior to June 2022 (Radiopharm Theranostics pipeline; June 2022)
- 24 Jun 2022 Radiopharm Theranostics plans a phase I trial in the US, in the second half of 2022 (Radiopharm Theranostics pipeline June 2022).